What to Look Out for when Transplanting T-Cell Prolymphocytic Leukemia

Acta Haematol. 2021;144(1):1-3. doi: 10.1159/000507415. Epub 2020 May 5.

Linus Wahnschaffe^{1

2

3}, Marco Herling^{4

5

6}

¹ Department I of Internal Medicine, Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, Cologne, Germany.
² Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
³ Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
⁴ Department I of Internal Medicine, Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, Cologne, Germany, marco.herling@uk-koeln.de.
⁵ Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany, marco.herling@uk-koeln.de.
⁶ Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany, marco.herling@uk-koeln.de.

No abstract available

Keywords: Allogeneic stem cell transplantation; Late relapse; T-cell prolymphocytic leukemia.

Publication types